603520.SHG Zhejiang Starry Pharm Co Ltd
- Market cap
- CNY 3.61B
- P/E
- 164.6x
- P/B
- 1.44x
- ROE
- 2.4%
- Dividend yield
- 4.05%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603520.SHG undervalued?
Graham numberThe Graham number of Zhejiang Starry Pharm Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Starry Pharm Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Starry Pharm Co Ltd yet.
Zhejiang Starry Pharm Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iodine-methyl, iodophorol, ioflufenicol, iopromide gadoxime meglumine, gadolinate dimeglumine, gadolinium,…
Full company profileZhejiang Starry Pharm Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Starry Pharm Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 673M | 711M | 890M | 1.31B | 1.37B | 2.00B | 2.13B | 2.20B | 2.35B | 2.45B | 2.68B |
| Gross Profit | 256M | 266M | 359M | 558M | 600M | 745M | 503M | 508M | 430M | 504M | 548M |
| Operating Income | 93.5M | 107M | 127M | 230M | 294M | 400M | -55.8M | 49.2M | -53.5M | 137M | 173M |
| EBITDA | 189M | 212M | 270M | 417M | 524M | 625M | 190M | 334M | 264M | 327M | 155M |
| Net Income | 76.1M | 83.1M | 93.7M | 170M | 239M | 324M | -75.8M | 44.2M | -49.1M | 10.2M | 60.2M |
| EPS | 0.25 | 0.25 | 0.29 | 0.51 | 0.71 | 0.94 | -0.22 | 0.13 | -0.12 | 0.02 | 0.14 |
| Balance Sheet | |||||||||||
| Total Assets | 1.89B | 2.01B | 3.07B | 3.48B | 4.41B | 4.90B | 5.30B | 5.52B | 6.05B | 6.16B | 5.84B |
| Total Liabilities | 1.07B | 1.14B | 2.14B | 2.46B | 2.54B | 2.68B | 3.53B | 3.76B | 3.41B | 3.59B | 3.37B |
| Shareholders' Equity | 810M | 857M | 891M | 996M | 1.82B | 2.17B | 1.77B | 1.75B | 2.63B | 2.56B | 2.46B |
| Cash & Short-term Investments | 163M | 198M | 187M | 434M | 930M | 846M | 662M | 565M | 603M | 415M | 316M |
| Total Debt | 926M | 1.02B | 1.85B | 2.08B | 2.08B | 1.91B | 2.78B | 2.59B | 1.98B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.68M | 18.1M | 192M | 247M | 174M | 509M | -78.4M | 46.1M | 194M | 3.67M | - |
| Capital Expenditure | 189M | 90.6M | 162M | 133M | 153M | 304M | 472M | 266M | 481M | 269M | 106M |
| Free Cash Flow | -181M | -72.5M | 29.4M | 113M | 21.3M | 205M | -551M | -222M | -287M | -266M | 199M |
| Ratios | |||||||||||
| ROE | 9.4% | 9.7% | 10.5% | 17.1% | 13.1% | 14.9% | -4.3% | 2.5% | -1.9% | 0.4% | 2.4% |
| ROA | 4.0% | 4.1% | 3.1% | 4.9% | 5.4% | 6.6% | -1.4% | 0.8% | -0.8% | 0.2% | 1.0% |
| Net Profit Margin | 11.3% | 11.7% | 10.5% | 13.0% | 17.5% | 16.2% | -3.6% | 2.0% | -2.1% | 0.4% | 2.2% |
| Debt to Equity | 1.14x | 1.20x | 2.07x | 2.09x | 1.14x | 0.88x | 1.58x | 1.48x | 0.75x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Starry Pharm Co Ltd dividends
- Dividend yield
- 4.05%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 1,427.2%
- Ex-dividend date
- Sep 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 146M | 0.33 | 1,427.2% |
| 2024 | CNY 128M | 0.31 | - |
| 2023 | CNY 68.3M | 0.20 | 154.3% |
| 2022 | CNY 122M | 0.36 | - |
| 2021 | CNY 122M | 0.36 | 37.8% |
| 2020 | CNY 58.7M | 0.18 | 24.6% |
| 2019 | CNY 35.9M | 0.11 | 21.1% |
| 2018 | CNY 108M | 0.33 | 115.7% |
| 2017 | CNY 88.6M | 0.27 | 106.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 17, 2022.
Who owns Zhejiang Starry Pharm Co Ltd
- Insiders 20.62%
- Institutions 2.83%
- Public & others 76.56%
- Shares outstanding 438M
- Free float 327M
Zhejiang Starry Pharm Co Ltd company profile
- Company name
- Zhejiang Starry Pharm Co Ltd
- Ticker
- 603520.SHG
- ISIN
- CNE1000026N8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,905
- Fiscal year end
- December
- Address
- Modern Industrial Cluster Area, Taizhou, China, 317306
- Phone
- 86 576 8771 8628
- Website
- starrypharm.com
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iodine-methyl, iodophorol, ioflufenicol, iopromide gadoxime meglumine, gadolinate dimeglumine, gadolinium, and iohexol injections; contrast agent APIs and intermediates consisting of iohexol, iopamidol, iodixanol, iodimeperidine, iopromide, iodophorol, iodophorol hydrolysate, iohexol hydrolysate, gadobacterium meglumine iodide, and triiodoisophthaloyl chloride esters; levofloxacin hydrochloride, levofloxacin, levofluorocycloester, and levofluorocarboxylic acid; and CMO and CDMO series, including loxoprofen sodium, loxoprofen acid, trimethyliodosilane, 2-iodo-5-methylbenzoic acid, methyl o-iodobenzoate, and iodobenzene. It also engages in technology promotion and application; investment; physical education; and wholesale activities. Zhejiang Starry Pharmaceutical Co.,Ltd. was incorporated in 1997 and is headquartered in Taizhou, China.
Zhejiang Starry Pharm Co Ltd management
1- Mr. Weiyi ShenVice Chairman & GM · born 1980